Background Myocardial metabolism plays an important role in maintaining cardiac function. Patients with dilated cardiomyopathy (DCMP) exhibit alterations in myocardial metabolism characterized by increased myocardial glucose metabolism. This study aimed to evaluate effects on myocardial metabolism of angiotensin-II receptor blockers, olmesartan and valsartan, in patients with DCMP. Methods OVOID (a comparison study of Olmesartan and Valsartan effects on myocardial metabolism in patients with Dilated cardiomyopathy), an investigator-initiated, multicenter, randomized controlled study of DCMP patients with New York Heart Association (NYHA) class II-IV, was conducted. The primary outcome was myocardial glucose metabolism measured by standardized uptake value ratio (SUVR) at 6 months after treatment. To measure SUVR, 18F-fluoro-2-deoxyglucose (FDG) cardiac positron emission tomography (PET) was performed at baseline and six months after receiving the study agent. A total of 44 patients were randomized at a 1:1 ratio to receive olmesartan (at a dose of 20 mg once daily) or valsartan (at a dose of 160 mg twice daily) for 6 months, in addition to a recommended therapy. Results Baseline clinical characteristics and SUVR measured by 18F-FDG PET data did not differ significantly between olmesartan and valsartan groups. The average left ventricular ejection fraction (LVEF) of patients was 25.1±7.8. Among patients with DCMP who received olmesartan or valsartan for 6 months, LVEF significantly increased. However, it was not significantly different between the two groups. Six-month follow-up 18F-FDG PET showed that SUVR value was significantly lower in the olmesartan group than that in the valsartan (3.76 ± 2.12 versus 7.33 ± 4.08, P = 0.01). Conclusions Six months of olmesartan therapy significantly decreased myocardial glucose metabolism in DCMP patients compared to valsartan therapy for six months.

The authors have declared no competing interest.

ClinicalTrials.gov; NCT04174456; 18 November 2019

We include details of all funding supported in the work presented.

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

the Ethics Committee/Institutional Review Board of Dong-A University Hospital.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

Yes. We include a data availability statment in the manuscript.